

# Carolina Pellegrini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8447100/publications.pdf>

Version: 2024-02-01

80  
papers

2,307  
citations

201674

27  
h-index

243625

44  
g-index

80  
all docs

80  
docs citations

80  
times ranked

3492  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enteric Î±-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinsonâ€™s disease before brain pathology. <i>Npj Parkinson's Disease</i> , 2022, 8, 9.	5.3	36
2	Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. <i>Inflammation</i> , 2022, 45, 1829-1847.	3.8	11
3	Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling. <i>Nephrology</i> , 2022, 27, 673-680.	1.6	11
4	Adenosine Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1270, 145-167.	1.6	18
5	NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. <i>Medicinal Research Reviews</i> , 2021, 41, 1890-1926.	10.5	28
6	DONEPEZIL IMPROVES VASCULAR FUNCTION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. <i>Journal of Hypertension</i> , 2021, 39, e21.	0.5	0
7	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6325.	4.1	5
8	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of dietâ€­induced obesity. <i>British Journal of Pharmacology</i> , 2021, 178, 3924-3942.	5.4	9
9	LRRK2 is reduced in Parkinsonâ€™s disease gut. <i>Acta Neuropathologica</i> , 2021, 142, 601-603.	7.7	7
10	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimerâ€™s Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 748021.	3.5	13
11	Donepezil improves vascular function in a mouse model of Alzheimerâ€™s disease. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00871.	2.4	4
12	From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinsonâ€™s disease. <i>European Journal of Histochemistry</i> , 2021, 65, .	1.5	6
13	Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome. <i>Frontiers in Pharmacology</i> , 2021, 12, 808400.	3.5	0
14	Protective effects of the combination <i>Bifidobacterium longum</i> plus lactoferrin against NSAID-induced enteropathy. <i>Nutrition</i> , 2020, 70, 110583.	2.4	16
15	Colonic dysmotility and inflammation associated with high fat diet-induced obesity: role of the enteric glia. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	1.0	0
16	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9199.	4.1	35
17	Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship. <i>Cells</i> , 2020, 9, 1772.	4.1	22
18	Inflammatory Bowel Diseases: It's Time for the Adenosine System. <i>Frontiers in Immunology</i> , 2020, 11, 1310.	4.8	7

#	ARTICLE	IF	CITATIONS
19	The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5089.	4.1	16
20	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3523.	4.1	24
21	Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation. <i>Pharmacological Research</i> , 2020, 159, 104938.	7.1	21
22	NKG2A and COVID-19: another brick in the wall. <i>Cellular and Molecular Immunology</i> , 2020, 17, 672-674.	10.5	72
23	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. <i>Progress in Neurobiology</i> , 2020, 191, 101806.	5.7	87
24	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 687-703.	5.0	9
25	Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. <i>Pharmacological Reports</i> , 2020, 72, 1347-1357.	3.3	4
26	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. <i>Cells</i> , 2020, 9, 1509.	4.1	13
27	Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches. <i>Trends in Molecular Medicine</i> , 2020, 26, 1021-1033.	6.7	16
28	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1296-1305.	2.4	30
29	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. <i>Neurobiology of Disease</i> , 2020, 139, 104821.	4.4	28
30	Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. <i>FASEB Journal</i> , 2020, 34, 5512-5524.	0.5	31
31	Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling. <i>Obesity</i> , 2020, 28, 609-615.	3.0	17
32	Editorial: IBD Management—Novel Targets and Therapeutic Perspectives. <i>Frontiers in Pharmacology</i> , 2020, 11, 448.	3.5	2
33	Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?. <i>Frontiers in Pharmacology</i> , 2020, 11, 621955.	3.5	7
34	Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. <i>Cells</i> , 2020, 9, 1245.	4.1	20
35	Intestinal epithelial barrier and neuromuscular compartment in health and disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1564-1597.	3.3	28
36	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , 2019, 43, 331-343.	3.4	27

#	ARTICLE	IF	CITATIONS
37	High Levels of $\beta$ -Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-16.	4.0	18
38	Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2876.	4.1	67
39	OC.05.3 HISTOMORPHOLOGICAL AND MOLECULAR CHARACTERIZATION OF PARKINSON'S DISEASE PATIENTS WITH CONSTIPATION: A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e89.	0.9	0
40	Ti3SiC2-Cf composites by spark plasma sintering: Processing, microstructure and thermo-mechanical properties. <i>Journal of the European Ceramic Society</i> , 2019, 39, 2824-2830.	5.7	28
41	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. <i>Translational Neurodegeneration</i> , 2019, 8, 5.	8.0	54
42	Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. <i>Purinergic Signalling</i> , 2018, 14, 27-36.	2.2	19
43	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , 2018, 9, 1340.	3.5	35
44	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. <i>Frontiers in Pharmacology</i> , 2018, 9, 1405.	3.5	33
45	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. <i>Frontiers in Pharmacology</i> , 2018, 9, 1094.	3.5	46
46	USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation. <i>EMBO Reports</i> , 2018, 19, .	4.5	131
47	Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. <i>Acta Neuropathologica</i> , 2018, 136, 345-361.	7.7	167
48	Neuronal regulation of intestinal immune functions in health and disease. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13406.	3.0	15
49	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. <i>PLoS ONE</i> , 2018, 13, e0195502.	2.5	47
50	Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. <i>Nutrition Research Reviews</i> , 2018, 31, 239-247.	4.1	40
51	The flavonoid compound luteolin prevents endothelial dysfunction in a mouse model of high fat diet-induced obesity. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-2-47.	0.0	0
52	FA-5, a novel AMP-activated protein kinase (AMPK) activator, as a new pharmacological tool for the management of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-2.	0.0	0
53	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-28.	0.0	0
54	A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-6-29.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3656-3671.	6.4	131
56	Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. <i>Gastroenterology</i> , 2017, 152, S180.	1.3	1
57	Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity. <i>Gastroenterology</i> , 2017, 152, S828.	1.3	0
58	Enteric Protective Effects of the Combination Bifidobacterium Longum and Lactoferrin in a Rat Model of Diclofenac-Induced Intestinal Injury. <i>Gastroenterology</i> , 2017, 152, S415.	1.3	0
59	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Neuropharmacology</i> , 2017, 123, 22-33.	4.1	15
60	Effects of L-DOPA/Benserazide Co-Treatment on Colonic Dysmotility and Enteric Inflammation Following Dopaminergic Nigrostriatal Neurodegeneration. <i>Gastroenterology</i> , 2017, 152, S179-S180.	1.3	0
61	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. <i>Purinergic Signalling</i> , 2017, 13, 497-510.	2.2	30
62	Mechanisms Underlying the Non-Anticoagulant Effects of Apixaban and Dabigatran on the Integrity of Intestinal Mucosa: A Comparative Pre-Clinical Study. <i>Gastroenterology</i> , 2017, 152, S414-S415.	1.3	0
63	P2X7 receptorâ€dependent tuning of gut epithelial responses to infection. <i>Immunology and Cell Biology</i> , 2017, 95, 178-188.	2.3	35
64	Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2017, 8, 36.	4.8	151
65	Sa1702 Alterations of Colonic Neuromuscular Excitatory Tachykininergic Pathways in a Mouse Model of Diet Induced-Obesity. <i>Gastroenterology</i> , 2016, 150, S351.	1.3	0
66	Sa1694 Colonic Inflammation in Experimental Parkinson's Disease: Evidence of Altered Colonic Tachykininergic Neurotransmissio. <i>Gastroenterology</i> , 2016, 150, S349.	1.3	0
67	Su1193 Rifaximin Prevents Enteric Bacteria Alterations and Inflammation in a Rat Model of Diclofenac-Induced Enteropathy. <i>Gastroenterology</i> , 2016, 150, S491-S492.	1.3	0
68	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1781-1791.	3.0	41
69	Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Journal of Neuroinflammation</i> , 2016, 13, 146.	7.2	77
70	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. <i>Gastroenterology</i> , 2016, 150, S968-S969.	1.3	3
71	Enteric Dysfunctions in Experimental Parkinsons Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 233-243.	2.5	49
72	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , 2016, 104, 186-196.	7.1	30

#	ARTICLE	IF	CITATIONS
73	The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 179-191.	3.4	41
74	Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon. <i>PLoS ONE</i> , 2015, 10, e0144630.	2.5	96
75	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1407-1414.	2.2	56
76	Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats. <i>PLoS ONE</i> , 2014, 9, e116253.	2.5	41
77	Role of the $A_{2B}$ receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 1314-1329.	5.4	26
78	P022 Role of P2X7 purinergic receptor in the control of enteric neuromuscular functions in normal rat distal colon and experimental bowel inflammation. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S73.	1.3	0
79	NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 86-95.	2.5	44
80	The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation and potential therapeutic applications. , 2013, 139, 157-188.		60